ALNY News and Press, Alnylam Pharmaceuticals Inc. From 02/28/22

PBE is neither suitable for income seekers, nor for long term investors. Despite being a Genomic revolution fund, it lacks focus, and invested heavily on large cap diverse biotechnology companies. Better biotechnology ETFs of similar nature are available in the market. For f...

– Documentary Explores the Physical, Mental and Psychosocial Impact of Acute Hepatic Porphyria (AHP), a Rare, Genetic Disease – – Viewers Encouraged to “Tell 15” People about Film to Shorten the 15 Years It Can Take to Diagnose AHP – ...

FBT is a passive biotechnology ETF, which doesn’t pay any dividend. Baring the past one year, FBT’s price return has outperformed the S&P 500. Effective portfolio rebalancing may determine its future growth. For further details see: FBT: A Long Term Hol...

With tensions rising between Russia and Ukraine the JPMorgan Chase macro research team screened Tuesday for stocks facing positive and negative impacts from the situation. "Russia-Ukraine tension is a low earnings risk for US corporates, but an Energy price shock amidst an aggressive central ...

The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Alnylam Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call Presentation

Alnylam has multiple clinical read-outs coming over the next 12 months that can meaningfully drive the shares, including the APOLLO-B study in mid-22. Zilebesiran is the highest-potential drug that I see in the pipeline today, with Phase II monotherapy data due before year-end. St...

Vir Biotechnology and GlaxoSmithKline expect to develop 2 million doses of Covid-19 antiviral Sotrovimab in the 1st half of 2022, with more to follow in the 2nd half of 2022. An Emergency Use Authorization of Sotrovimab has been filed as an intramuscular injection for patients with mi...

3 Top Health Care Stocks To Watch Right Now As the stock market continues to show volatility, some investors may flock to more defensive stocks such as health care stocks . Admittedly, the current global pandemic does influence the sentiment around the health care sector. Howeve...

Several Street firms are maintaining bullish views on Alnylam Pharmaceuticals (ALNY -0.7%) following the biotech's Q4 2021 earnings results Thursday. Piper Sandler's Edward Tenthoff is maintaining his overweight rating and $208 price target (~38% upside based on Thursday's close). He said he ...

HQL pays quarterly dividends. Even during the pandemic, its performance has been better than its peers. Current prices look attractive. For further details see: Tekla Life Sciences Investors: Buy For Steady, Quarterly Dividend